Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer Agrees to Invest US$300 Mln in Joint R&D With S. Korea (South Korea)

This article was originally published in PharmAsia News

Executive Summary

Pfizer has signed a preliminary deal with South Korea's government to invest $300 million in joint drug research and development, from animal testing to clinical research projects, over the next five years. The research will be conducted at various local centers in South Korea through 2012. If finalized, Pfizer's deal will make it the single largest research-and-development foreign investor in South Korea. (Click here for more

Table

View full table

Tags:
Latest Headlines

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

See All
UsernamePublicRestriction

Register

SC066291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By